home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410m.zip
/
M94A2283.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
39 lines
Document 2283
DOCN M94A2283
TI GEM 91: therapeutic agent for AIDS based on antisense oligonucleotide
approach.
DT 9412
AU Agrawal S; Tang JY; Lisziewicz J; Gallo RC; Hybridon, Inc., Worcester,
MA.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):34 (abstract no. 109A). Unique
Identifier : AIDSLINE ICA10/94370292
AB Gene expression modulator 91 (GEM 91) is an oligonucleotide
phosphorothioate (25-mer) designed to bind to the initiation site of gag
gene. This site is found to be very conserved among various patient
HIV-1 isolates and is critical for packaging of the virus. GEM 91 is
rapidly taken up by various lymphocytes and is stable under
physiological conditions. GEM 91 has been studied for its anti-HIV
activity using laboratory as well as various primary isolates of HIV-1
using MOLT-3, CEM, H9, PBMCs and macrophages. GEM 91 inhibited the virus
replication in a sequence specific and dose dependent manner. GEM 91 is
also found to be effective against AZT resistant primary HIV-1 isolates.
Pharmacokinetic studies in mice, rats and monkeys have been performed
and showed that GEM 91, if administered intravenously, is bioavailable
in most of the organs, and half life of plasma clearance is in the range
of 30-50 hours. In an acute toxicity study, GEM 91 has been administered
to mice and rats at a dose of 500 mg/kg (intravenously) and up to a dose
of 20 mg/kg (slow infusion), and found to be well tolerated. Presently,
GEM 91 is in Phase I clinical trials at Agence Nationale de Recherches
sur le SIDA (ANRS) in Paris. GEM 91 is also a clinical candidate at the
AIDS Clinical Trial Group (ACTG) of NIAID, USA.
DE Acquired Immunodeficiency Syndrome/*DRUG THERAPY Animal Antiviral
Agents/*THERAPEUTIC USE Dose-Response Relationship, Drug Half-Life
Haplorhini Mice Oligonucleotides, Antisense/ADMINISTRATION & DOSAGE/
PHARMACOKINETICS/*THERAPEUTIC USE Rats Thionucleotides/ADMINISTRATION
& DOSAGE/PHARMACOKINETICS/ *THERAPEUTIC USE Virus Replication/DRUG
EFFECTS CLINICAL TRIAL CLINICAL TRIAL, PHASE I MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).